Compare RBKB & FOCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBKB | FOCL |
|---|---|---|
| Founded | 1860 | N/A |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.9M | 203.7M |
| IPO Year | 2018 | 1998 |
| Metric | RBKB | FOCL |
|---|---|---|
| Price | $12.75 | $4.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 226.4K | 174.0K |
| Earning Date | 04-23-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 215.00 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | $2,984,000.00 | ★ $70,527,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.05 | ★ N/A |
| Revenue Growth | N/A | ★ 1.63 |
| 52 Week Low | $9.41 | $4.09 |
| 52 Week High | $17.99 | $6.40 |
| Indicator | RBKB | FOCL |
|---|---|---|
| Relative Strength Index (RSI) | 37.43 | 29.58 |
| Support Level | $11.63 | N/A |
| Resistance Level | $17.78 | $5.64 |
| Average True Range (ATR) | 0.30 | 0.33 |
| MACD | 0.20 | -0.23 |
| Stochastic Oscillator | 87.12 | 11.47 |
Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank, which is a New York-chartered stock savings bank. It provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management. The Bank's primary business activity is accepting deposits from the general public and using those funds together with borrowings, to originate commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and indirect automobile loans, and to purchase one- to four-family residential real estate loans and investment securities.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.